Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders

News
2023
2022
Archive

January 5, 2023

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
January 5, 2023

Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
January 5, 2023

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
December 20, 2022

IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board
December 20, 2022

Arvinas Announces Changes to its Board of Directors
December 19, 2022

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
December 15, 2022

Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using Reset®at AAAP
December 15, 2022

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
December 12, 2022

IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161
December 9, 2022

Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th Ga2len Global Urticaria Forum

© 2023 5AM Venture Management LLC